Evidence map›Paper›PMID 37496317›Full record

ArticleCancer medicine2023

Impact of the COVID-19 pandemic on paediatric renal tumour presentation and management, a SIOP renal tumour study group study.

Prakriti Roy, Sophie E van Peer, Rana Dandis, Catriona Duncan, Joaquim Caetano de Aguirre-Neto, Arnauld Verschuur, Beatriz de Camargo, Henrike E Karim-Kos, Luna Boschetti, Filippo Spreafico and 5 more

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 7 countries.

Prakriti RoyPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Sophie E van PeerPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0001-5484-9112
Rana DandisPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Catriona DuncanGreat Ormond Street Hospital for Children, London, UK.
Joaquim Caetano de Aguirre-NetoPaediatric Haemato-oncology, Hospital Santa Casa de Belo Horizonte, Belo Horizonte, Brazil.
Arnauld VerschuurDepartment of Paediatric Oncology & Haematology, La Timone Children's Hospital, Marseille, France.
Beatriz de CamargoGrupo Brasileiro de Tumores Renais (Brazilian Renal Tumor Group), São Paulo, Brazil.ORCID 0000-0002-5794-1042
Henrike E Karim-KosPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Luna BoschettiDepartment of Medical Oncology and Hematology, Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milan, Milan, Italy.
Filippo SpreaficoDepartment of Medical Oncology and Hematology, Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milan, Milan, Italy.
Gema L Ramirez-VillarDepartment of Paediatric Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain.
Norbert GrafDepartment of Paediatric Oncology & Haematology, Saarland University, Homburg, Germany.ORCID 0000-0002-2248-323X
Harm van TinterenPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Kathy Pritchard-JonesUCL Great Ormond Street Institute of Child Health, University College London, London, UK.ORCID 0000-0002-2384-9475
Marry M van den Heuvel-EibrinkPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Princess Máxima Center · NLFondazione IRCCS Istituto Nazionale dei Tumori · ITGreat Ormond Street Hospital · GBGrupo Santa Casa de Belo Horizonte · BRHôpital de la Timone · FRHospital Universitario Virgen del Rocío · ESSaarland University · DEUniversity College London · GBUniversity Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic had global catastrophic effects on the management of non-communicable diseases including paediatric cancers. Restrictions during the start of 2020 complicated timely referrals of patients to specialized centres. We aimed to evaluate the pandemic's impact on the number of new diagnoses, disease characteristics and management delay for paediatric renal tumour patients included in the SIOP-RTSG-UMBRELLA study, as compared with data from a historical SIOP-RTSG trial (2005-2009).

methodsThe number of intensive care admissions, population mobility rates and national lockdown periods/restrictions were used as proxies of the pandemic's severity and impact on societies. Clinical and tumour data were extracted from the SIOP-RTSG-UMBRELLA study and from historical SIOP-RTSG trials.

resultsDuring the first lockdown in Europe, the number of newly diagnosed patients decreased following restrictions and population immobilisation. Additionally, there was a higher proportion of advanced disease (37% vs. 17% before and after COVID-9, p < 0.001) and larger median tumour volume (559 cm

conclusionThe COVID-19 pandemic briefly changed the tumour characteristics of children presenting with renal tumours. The longer-term impact on clinical outcomes will be kept under review.

Indexed as

COVID-19Kidney NeoplasmsChildCommunicable Disease ControlHumansPandemicsRadionuclide Imagingchildhood cancerCOVID-19 pandemicglobal pandemicnephroblastomaSARS-CoV-2-infectionWilms tumour

Identifiers

PMID37496317
PMCPMC10501283
OpenAlexW4385294858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.